Lethal hemolytic anemia-genital anomalies syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1046OMIM:600461D58.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Lethal hemolytic anemia-genital anomalies syndrome is an extremely rare genetic condition that combines severe destruction of red blood cells (hemolytic anemia) with abnormalities of the genital organs. This syndrome was first described in a small number of affected individuals and is considered lethal, meaning it typically leads to death in early life. The hemolytic anemia component means that the body destroys its own red blood cells faster than it can make new ones, leading to severe anemia, jaundice (yellowing of the skin and eyes), and organ damage. The genital anomalies can include malformations of the reproductive organs. Because this condition is so rare, very little is known about its full range of symptoms, the exact genetic cause, or effective treatments. Management is primarily supportive, focusing on treating the anemia through blood transfusions and addressing any complications that arise. Due to the severity of the anemia and associated problems, the prognosis is very poor, with affected infants typically not surviving the newborn period or early infancy. Families affected by this condition should seek care from specialists in genetics, hematology, and neonatology for the best possible supportive care.

Also known as:

Key symptoms:

Severe anemia (very low red blood cell count)Jaundice (yellow skin and eyes)Destruction of red blood cells (hemolysis)Abnormalities of the genitalsPale skinDifficulty breathingSwelling of the body (hydrops)Enlarged spleenEnlarged liverPoor feedingFailure to thrive

Clinical phenotype terms (20)— hover any for plain English
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Lethal hemolytic anemia-genital anomalies syndrome.

View clinical trials →

No actively recruiting trials found for Lethal hemolytic anemia-genital anomalies syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Lethal hemolytic anemia-genital anomalies syndrome community →

No specialists are currently listed for Lethal hemolytic anemia-genital anomalies syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Lethal hemolytic anemia-genital anomalies syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Lethal hemolytic anemia-genital anomalies syndromeForum →

No community posts yet. Be the first to share your experience with Lethal hemolytic anemia-genital anomalies syndrome.

Start the conversation →

Latest news about Lethal hemolytic anemia-genital anomalies syndrome

No recent news articles for Lethal hemolytic anemia-genital anomalies syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is the expected course of this condition for my baby?,Are there any treatments that could help improve my baby's comfort or survival?,What genetic testing is available to confirm the diagnosis?,What is the chance that future children could be affected by this condition?,Can you refer us to palliative care and family support services?,Is prenatal testing available for future pregnancies?,Are there any research studies or registries we can participate in?

Common questions about Lethal hemolytic anemia-genital anomalies syndrome

What is Lethal hemolytic anemia-genital anomalies syndrome?

Lethal hemolytic anemia-genital anomalies syndrome is an extremely rare genetic condition that combines severe destruction of red blood cells (hemolytic anemia) with abnormalities of the genital organs. This syndrome was first described in a small number of affected individuals and is considered lethal, meaning it typically leads to death in early life. The hemolytic anemia component means that the body destroys its own red blood cells faster than it can make new ones, leading to severe anemia, jaundice (yellowing of the skin and eyes), and organ damage. The genital anomalies can include malfo

How is Lethal hemolytic anemia-genital anomalies syndrome inherited?

Lethal hemolytic anemia-genital anomalies syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Lethal hemolytic anemia-genital anomalies syndrome typically begin?

Typical onset of Lethal hemolytic anemia-genital anomalies syndrome is neonatal. Age of onset can vary across affected individuals.